Echothiophate API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Echothiophate API 6736-03-4?
- Description:
- Here you will find a list of producers, manufacturers and traders of Echothiophate. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Echothiophate
- Synonyms:
- Echothiophate , Ecothiopatum , Phospholine
- Cas Number:
- 6736-03-4
- DrugBank number:
- DB01057
- Unique Ingredient Identifier:
- 0F350BVT6S
About Echothiophate
More information about the use of: Echothiophate. A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements
Echothiophate is a type of Cholinesterase inhibitors
Cholinesterase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various medical conditions. These compounds work by inhibiting the activity of the enzyme cholinesterase, which breaks down the neurotransmitter acetylcholine in the body.
Acetylcholine is involved in many important processes in the central and peripheral nervous systems, including muscle contractions, memory, and cognitive functions. By inhibiting cholinesterase, these APIs help to increase the levels of acetylcholine in the brain and enhance cholinergic neurotransmission.
Cholinesterase inhibitors have proven to be highly effective in the management of Alzheimer's disease, a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. These APIs, such as donepezil, rivastigmine, and galantamine, are commonly used as symptomatic treatments to alleviate cognitive impairment and enhance patients' overall quality of life.
Furthermore, cholinesterase inhibitors find applications beyond Alzheimer's disease. They are also utilized in the treatment of other conditions, including Parkinson's disease, glaucoma, myasthenia gravis, and certain types of dementia.
The development and utilization of cholinesterase inhibitors have revolutionized the treatment options for patients suffering from these debilitating disorders. As research in neuroscience and pharmacology advances, the continuous refinement of cholinesterase inhibitors and the discovery of novel compounds within this subcategory hold promise for future therapeutic breakthroughs.
Echothiophate (Cholinesterase inhibitors), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
